150 related articles for article (PubMed ID: 15052701)
21. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
23. NDA submitted for new formulation of saquinavir.
AIDS Patient Care STDS; 1997 Aug; 11(4):288-9. PubMed ID: 11361847
[No Abstract] [Full Text] [Related]
24. [A further option in PI therapy. Approval of a new protease inhibitor in the USA].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868
[No Abstract] [Full Text] [Related]
25. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
26. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
27. Saquinavir with low-dose ritonavir twice daily.
TreatmentUpdate; 2002; 14(4):2-3. PubMed ID: 12064312
[No Abstract] [Full Text] [Related]
28. Kaletra lower-strength pediatric tablet approved in Europe.
AIDS Patient Care STDS; 2008 May; 22(5):437-8. PubMed ID: 18521973
[No Abstract] [Full Text] [Related]
29. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
30. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M
J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
[TBL] [Abstract][Full Text] [Related]
31. New Norvir soft-gel capsule formulation approved by FDA.
Gaylord G
Posit Living; 1999 Aug; 8(7):11. PubMed ID: 12492076
[No Abstract] [Full Text] [Related]
32. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
[TBL] [Abstract][Full Text] [Related]
33. Different combinations of ritonavir-indinavir.
TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
[No Abstract] [Full Text] [Related]
34. They are back.
Res Initiat Treat Action; 1999 Oct; 5(4):19. PubMed ID: 11366940
[TBL] [Abstract][Full Text] [Related]
35. Why the old saquinavir (Invirase) may be bad for your health.
Vazquez E
Posit Aware; 1997; 8(4):28-31. PubMed ID: 11364485
[TBL] [Abstract][Full Text] [Related]
36. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
37. New dosing regimen approved.
AIDS Patient Care STDS; 2002 Apr; 16(4):190. PubMed ID: 12015873
[No Abstract] [Full Text] [Related]
38. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
[TBL] [Abstract][Full Text] [Related]
39. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
[TBL] [Abstract][Full Text] [Related]
40. Fortovase approved: new saquinavir formulation.
James JS
AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
